Moderna has unveiled its first in vivo CAR-T program. Building on other groups’ ex vivo CAR-T data, the company plans to start clinical development of an off-the-shelf autoimmune disease prospect, ...

As Moderna reshapes itself in the wake of the pandemic, the company on Thursday passed a key milestone in its bid to expand the reach of its mRNA platform to the massive influenza vaccination market.

June 18 (Reuters) - The U.S. Food and Drug Administration's advisory panel is set to vote on whether the benefits of Moderna's flu vaccine outweigh its risks in older ‌adults, after regulators ...

FDA advisers back mFlusiva's benefits for adults 50 and up The agency initially rejected Moderna's application An FDA decision on approval is expected by August 5 It would be the first US seasonal ...

Moderna (MRNA) shares surged nearly ~15% on Friday to around ~$69 and are now up almost ~42% over the past month. The Moderna stock rally came after the company shared a major business update on its ...

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class to its R&D capabilities. It has nominated a lead candidate in the in vivo ...

Advisers to the Food and Drug Administration have thrown their support behind an experimental flu shot from Moderna, heightening the chance that the vaccine could soon complete a dramatic regulatory ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Among all the awards and mementos Moderna ...

A Food and Drug Administration advisory panel on Thursday recommended the approval of Moderna’s mRNA-based flu shot for older adults. Subscribe to read this story ad-free Get unlimited access to ...

Moderna Inc. Chief Executive Officer Stephane Bancel said he sees the pending launch of a planned flu vaccine as a chance to start a public conversation about how mRNA technology can offer better ...

Moderna has touted the potential of its ever-expanding mRNA platform, which includes an in vivo candidate, during its annual Science Day. Held on 25 June, Moderna told participants that it will ...

Independent advisors for the Food and Drug Administration on Friday voted 9–0 in support of approving Moderna’s seasonal mRNA flu vaccine, which a Trump appointee at the agency initially tried to ...